Europe has more cancer start-ups than the US, but American firms file more patents and have better access to capital
Photo credits: chanwity / BigStock
While Europe has held a strong position in high-tech cancer innovation in the past, a report published on Monday by the European Patent Office (EPO) suggests that the bloc has lost its leading role to the United States.
The EPO analysis shows that Europe boasts a higher number of oncology-related start-ups than the US, but has a lower stock of related intellectual property. Since 2010, US start-ups have registered 11,325 international patent families (IPFs) related to cancer treatment and diagnosis, 2.7 times more than EU oncology start-ups and 1.7 times more than all European start-ups combined.
Discover the latest in research funding every Tuesday with Funding Newswire. Dive into detailed articles with our monthly or yearly subscriptions or start with a free trial
NOTE: if you're a part of one of our Network member organisations, you get free access by signing up with your institutional email. Verify your eligibility here.
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.